Graves Disease Market Size, Share, Trends, Growth Outlook

Graves Disease Market is estimated to increase at a Compounded Annual Growth Rate of 4.3% CAGR over the forecast period from 2024 to 2030

The Graves Disease Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Diagnosis (Ultrasound, Imaging Test, Radioactive Iodine Uptake, Blood Sample), By Treatment (Anti-Thyroid Medication, Radioactive Iodine Therapy, Surgery).

An Introduction to Graves Disease Market in 2024

Graves' disease, an autoimmune disorder characterized by hyperthyroidism and ophthalmic manifestations, remains a significant clinical challenge in endocrinology. In 2024, the management of Graves' disease is characterized by a multidisciplinary approach, encompassing medical therapy, radioactive iodine therapy, and thyroidectomy, tailored to individual patient needs and preferences. Antithyroid drugs such as methimazole and propylthiouracil continue to be first-line treatments for achieving euthyroidism and ameliorating hyperthyroid symptoms, with ongoing research focused on optimizing dosing regimens and minimizing adverse effects. Additionally, advances in radioiodine therapy techniques, including dosimetry calculations and personalized treatment planning, aim to maximize therapeutic efficacy while minimizing the risk of hypothyroidism and radiation-related complications. With the recognition of Graves' disease as a chronic condition requiring long-term management and surveillance, integrated care models involving endocrinologists, ophthalmologists, and primary care providers are essential for optimizing outcomes and improving quality of life for patients living with this complex autoimmune disorder.

Market Trend: Increasing Adoption of Targeted Therapies and Biologics

A significant trend in the market for Graves' disease is the increasing adoption of targeted therapies and biologics. With advancements in understanding the pathophysiology of Graves' disease, there's a notable shift towards the development and utilization of targeted immunomodulatory agents, such as monoclonal antibodies and biologics, for the management of hyperthyroidism and associated complications. These targeted therapies offer advantages such as improved efficacy, reduced side effects, and better disease management compared to conventional treatments like antithyroid drugs and radioactive iodine therapy. The trend towards targeted therapies reflects the evolving treatment landscape and the growing emphasis on personalized medicine in autoimmune disorders like Graves' disease.

Market Driver: Rising Prevalence of Autoimmune Disorders and Thyroid Dysfunction

The primary driver propelling the market for Graves' disease is the rising prevalence of autoimmune disorders and thyroid dysfunction globally. Graves' disease, an autoimmune condition characterized by hyperthyroidism, affects millions of individuals worldwide, with a higher incidence among women and older adults. Factors such as genetic predisposition, environmental triggers, and hormonal imbalances contribute to the development of Graves' disease, driving the need for effective treatment options to manage symptoms and prevent disease progression. As the burden of autoimmune disorders and thyroid dysfunction continues to grow, there's a corresponding increase in the demand for diagnostic tests, therapeutic interventions, and supportive care services for individuals living with Graves' disease, thus fueling market growth in the field of thyroid disorders.

Market Opportunity: Development of Novel Immunomodulatory Therapies

An untapped opportunity within the market for Graves' disease lies in the development of novel immunomodulatory therapies targeting specific pathways involved in autoimmune thyroid disease. While current treatments for Graves' disease focus on suppressing thyroid hormone production or modulating thyroid function, there's potential to explore innovative approaches that target the underlying autoimmune processes driving disease pathology. By developing immunomodulatory agents that selectively inhibit autoantibody production, modulate immune cell activation, or restore immune tolerance, manufacturers can offer novel treatment options that address the root cause of Graves' disease and provide long-term remission or disease control. Additionally, advancements in precision medicine, biomarker discovery, and therapeutic targeting present opportunities to tailor treatment regimens to individual patient profiles, optimizing efficacy and minimizing adverse effects. Embracing the opportunity to develop novel immunomodulatory therapies aligns to improve outcomes and quality of life for individuals living with Graves' disease while advancing the field of autoimmune thyroid disorders.

Graves Disease Market Share Analysis: Radioactive Iodine Uptake is the fastest growing segment over the forecast period to 2030

The fastest-growing segment in the Graves Disease Market is Radioactive Iodine Uptake (RAIU) as a diagnostic method. This growth is primarily driven by the increasing adoption of nuclear medicine techniques and advancements in imaging technology. RAIU tests offer a comprehensive assessment of thyroid function and are often preferred due to their accuracy in diagnosing hyperthyroidism, including Graves Disease. Additionally, the non-invasive nature of RAIU tests and their ability to provide valuable insights into thyroid activity contribute to their rising demand and growth within the market.

Graves Disease Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, bioMérieux SA, F. Hoffmann-La Roche Ltd, Horizon Therapeutics plc, Institute of Isotopes Co. Ltd, Jubilant Pharma Holdings Inc, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Thermo Fisher Scientific Inc

Graves Disease Market Segmentation

By Diagnosis
Ultrasound
Imaging Test
Radioactive Iodine Uptake
Blood Sample
By Treatment
Anti-Thyroid Medication
Radioactive Iodine Therapy
Surgery
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Graves Disease Market Companies

Abbott Laboratories
bioMérieux SA
F. Hoffmann-La Roche Ltd
Horizon Therapeutics plc
Institute of Isotopes Co. Ltd
Jubilant Pharma Holdings Inc
Novartis AG
Pfizer Inc
Sun Pharmaceutical Industries Ltd
Thermo Fisher Scientific Inc

Reasons to Buy the Graves Disease Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Graves Disease Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Graves Disease Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Graves Disease Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Graves Disease Market Size Outlook, $ Million, 2021 to 2030
3.2 Graves Disease Market Outlook by Type, $ Million, 2021 to 2030
3.3 Graves Disease Market Outlook by Product, $ Million, 2021 to 2030
3.4 Graves Disease Market Outlook by Application, $ Million, 2021 to 2030
3.5 Graves Disease Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Graves Disease Industry
4.2 Key Market Trends in Graves Disease Industry
4.3 Potential Opportunities in Graves Disease Industry
4.4 Key Challenges in Graves Disease Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Graves Disease Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Graves Disease Market Outlook by Segments
7.1 Graves Disease Market Outlook by Segments, $ Million, 2021- 2030
By Diagnosis
Ultrasound
Imaging Test
Radioactive Iodine Uptake
Blood Sample
By Treatment
Anti-Thyroid Medication
Radioactive Iodine Therapy
Surgery

8 North America Graves Disease Market Analysis and Outlook To 2030
8.1 Introduction to North America Graves Disease Markets in 2024
8.2 North America Graves Disease Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Graves Disease Market size Outlook by Segments, 2021-2030
By Diagnosis
Ultrasound
Imaging Test
Radioactive Iodine Uptake
Blood Sample
By Treatment
Anti-Thyroid Medication
Radioactive Iodine Therapy
Surgery

9 Europe Graves Disease Market Analysis and Outlook To 2030
9.1 Introduction to Europe Graves Disease Markets in 2024
9.2 Europe Graves Disease Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Graves Disease Market Size Outlook by Segments, 2021-2030
By Diagnosis
Ultrasound
Imaging Test
Radioactive Iodine Uptake
Blood Sample
By Treatment
Anti-Thyroid Medication
Radioactive Iodine Therapy
Surgery

10 Asia Pacific Graves Disease Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Graves Disease Markets in 2024
10.2 Asia Pacific Graves Disease Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Graves Disease Market size Outlook by Segments, 2021-2030
By Diagnosis
Ultrasound
Imaging Test
Radioactive Iodine Uptake
Blood Sample
By Treatment
Anti-Thyroid Medication
Radioactive Iodine Therapy
Surgery

11 South America Graves Disease Market Analysis and Outlook To 2030
11.1 Introduction to South America Graves Disease Markets in 2024
11.2 South America Graves Disease Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Graves Disease Market size Outlook by Segments, 2021-2030
By Diagnosis
Ultrasound
Imaging Test
Radioactive Iodine Uptake
Blood Sample
By Treatment
Anti-Thyroid Medication
Radioactive Iodine Therapy
Surgery
12 Middle East and Africa Graves Disease Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Graves Disease Markets in 2024
12.2 Middle East and Africa Graves Disease Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Graves Disease Market size Outlook by Segments, 2021-2030
By Diagnosis
Ultrasound
Imaging Test
Radioactive Iodine Uptake
Blood Sample
By Treatment
Anti-Thyroid Medication
Radioactive Iodine Therapy
Surgery

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
bioMérieux SA
F. Hoffmann-La Roche Ltd
Horizon Therapeutics plc
Institute of Isotopes Co. Ltd
Jubilant Pharma Holdings Inc
Novartis AG
Pfizer Inc
Sun Pharmaceutical Industries Ltd
Thermo Fisher Scientific Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Diagnosis
Ultrasound
Imaging Test
Radioactive Iodine Uptake
Blood Sample
By Treatment
Anti-Thyroid Medication
Radioactive Iodine Therapy
Surgery
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)